longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Sarepta Therap

SRPT

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Demand Stabilization Might Change The Case For Investing In Sarepta Stock (SRPT)

    Simplywall·2 days ago, 09:53 AM
    SRPT-2.71%SRPU0.00%
  • Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

    Market Beat·Sep 15 at 05:02 AM
    SRPT-2.71%SRPU0.00%
  • SRPT: Key pipeline data for FSHD and DM1 expected soon, with commercial stabilization underway

    Quartr·Sep 14 at 01:53 PM
    SRPT-2.71%SRPU0.00%
  • Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform

    Tip Ranks·Sep 8 at 07:45 PM
    SRPT-2.71%SRPU0.00%
  • A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

    benzinga_article·Sep 8 at 05:47 PM
    SRPT-2.71%NVS-0.39%
  • Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged

    Tip Ranks·Sep 8 at 04:35 PM
    SRPT-2.71%SRPU0.00%
  • Novartis's failed trial for cholesterol drug leads to broad biopharma selloff

    MarketWatch·Sep 8 at 01:53 PM
    AMGN+1.55%SRPT-2.71%
  • STOCKS | Nasdaq Biotechnology Index Falls More Than 2% at the Open

    CoinLive·Sep 8 at 01:44 PM
    ROIV-0.53%ARQT-4.08%
  • Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

    Unusual Whales·Sep 8 at 01:08 PM
    SRPT-2.71%SRPU0.00%
  • Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

    benzinga_article·Sep 8 at 12:01 PM
    - U.S. stock futures declined sharply during Tuesday's pre-market session, with Dow futures falling over 400 points. - Novartis shares tumbled 12.7 % after reporting that its pelacarsen phase III Lp(a) HORIZON trial failed to meet its primary endpoint. - Other notable movers included Ionis Pharmaceuticals dropping 11.5 % in sympathy and Dyne Therapeutics dipping 35.5 %.
    HAFN+4.12%SLN-3.94%
  • Biggest stock movers Tuesday: ZIM, NVS, and more

    businessinsider·Sep 8 at 09:31 AM
    DYN-5.26%NVS-0.39%
  • Weekly Recap | Sarepta Therap +7.86%, most brokers rate it hold

    Weekly Review·Sep 5 at 08:03 AM
    SRPT-2.71%
  • Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

    Unusual Whales·Sep 5 at 03:29 AM
    SRPT-2.71%SRPU0.00%
  • Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 6.6% - Should You Buy?

    Market Beat·Sep 2 at 04:41 PM
    SRPT-2.71%SRPU0.00%
  • US Biotech Firms Advance Pipelines as Vertex and Illumina Raise 2026 Forecasts

    Global Report·Sep 1 at 11:32 AM
    REGN-0.58%VRTX-1.55%